New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. These drugs have transformed the treatment of type 2 diabetes by helping lower blood sugar levels and even reducing the risk of ...

Semaglutide medications like Ozempic and Wegovy have shown proven results for managing conditions like type 2 diabetes and ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

Shell Canada's decision on whether to pursue Phase 2 of LNG Canada will depend on other opportunities that are available, ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

Novo Nordisk's flagship diabetes and weight-loss drugs, Ozempic and Wegovy, have come under heightened scrutiny after the ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...